ReviewAnnals of neurology2007
Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations.
Review in Annals of neurology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 215 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
215 citing papers in PubMed, 4 syntheses or guidelines pooled it, 569 citations in OpenAlex.
- Impact of systemic anticancer therapy in pediatric optic pathway glioma on visual function: A systematic review.PloS one · 2021Pooled it
- A systematic review of ongoing clinical trials in optic pathway gliomas.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2020Pooled it
- Management of incidental brain tumors in children: a systematic review.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2020Pooled it
- Current status and recommendations for biomarkers and biobanking in neurofibromatosis.Neurology · 2016Guideline
- Trial
- Natural history and management of low-grade glioma in NF-1 children.Journal of neuro-oncology · 2010Trial
- Article
- Cancer predisposition syndromes: an imaging review.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Review
- Molecular convergence enables precision medicine for pediatric low grade gliomas.Discover oncology · 2026Review
- Diencephalic Syndrome: Clinical Features, Pathophysiology, and Long-Term Outcomes.Children (Basel, Switzerland) · 2026Review
- Asthma-mediated control of optic glioma growth via T cell-microglia interactions: A mathematical model.NPJ systems biology and applications · 2026Article
- Current Perspectives on Pediatric Low-Grade Gliomas: Focus on BRAF and MEK Inhibition.Brain tumor research and treatment · 2026Review
- Standalone NF1: guiding the transition from paediatric to adult care.Drugs in context · 2026Article
- Impact of Optic Pathway Gliomas on Puberty and Growth in Neurofibromatosis Type 1: A 20-Year Experience From a Tertiary Center.Journal of child neurology · 2025Article
- Retinal Detachment in the Setting of Neurofibromatosis Type 1.Journal of vitreoretinal diseases · 2025Article
- MRI-based, three-dimensionally assessed tumor burden and growth velocity to predict visual acuity deterioration in optic pathway glioma - results of a retrospective longitudinal analysis.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2025Article
- Lifelong Management of Neurofibromatosis 1 Patients.Journal of Korean Neurosurgical Society · 2025Article
- Genetics and current research models of Mendelian tumor predisposition syndromes with ocular involvement.Progress in retinal and eye research · 2025Review
- Spontaneous regression of epileptogenic pilocytic astrocytoma with FGFR1-TACC1 fusion.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2025Article
- Case Report: Phenotypic heterogeneity within an NF1 family: assessment of the pathogenicity of aFrontiers in neuroscience · 2025Article
155 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
Optic pathway glioma (OPG), seen in 15% to 20% of individuals with neurofibromatosis type 1 (NF1), account for significant morbidity in young children with NF1. Overwhelmingly a tumor of children younger than 7 years, OPG may present in individuals with NF1 at any age. Although many OPG may remain indolent and never cause signs or symptoms, others lead to vision loss, proptosis, or precocious puberty. Because the natural history and treatment of NF1-associated OPG is different from that of sporadic OPG in individuals without NF1, a task force composed of basic scientists and clinical researchers was assembled in 1997 to propose a set of guidelines for the diagnosis and management of NF1-associated OPG. This new review highlights advances in our understanding of the pathophysiology and clinical behavior of these tumors made over the last 10 years. Controversies in both the diagnosis and management of these tumors are examined. Finally, specific evidence-based recommendations are proposed for clinicians caring for children with NF1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.